Artificial Intelligence in Urooncology: What We Have and What We Expect

被引:7
|
作者
Fron, Anita [1 ]
Semianiuk, Alina [1 ]
Lazuk, Uladzimir [1 ]
Ptaszkowski, Kuba [2 ]
Siennicka, Agnieszka [3 ]
Leminski, Artur [4 ]
Krajewski, Wojciech [1 ]
Szydelko, Tomasz [1 ]
Malkiewicz, Bartosz [1 ]
机构
[1] Wroclaw Med Univ, Univ Ctr Excellence Urol, Dept Minimally Invas & Robot Urol, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Physiotherapy, PL-50368 Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Physiol & Pathophysiol, PL-50556 Wroclaw, Poland
[4] Pomeranian Med Univ, Dept Urol & Urol Oncol, PL-70111 Szczecin, Poland
关键词
artificial intelligence; machine learning; urooncology; prostate cancer; RENAL-CELL CARCINOMA; PROSTATE-CANCER; TEXTURE ANALYSIS; MACHINE; DIAGNOSIS; RADIOMICS; PREDICTION; BIOPSIES; MODELS; TUMORS;
D O I
10.3390/cancers15174282
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Our study provides an overview of the current state of artificial intelligence applications in urooncology and explores potential future advancements in this field. With remarkable progress already achieved, artificial intelligence has revolutionized urooncology by facilitating image analysis, grading, biomarker research, and treatment planning. We also discuss types of artificial intelligence and their possible applications in the management of cancers such as prostate, kidney, bladder, and testicular. As artificial intelligence technology continues to evolve, it holds immense promise for further advancing urooncology and enhancing the care of patients with cancer.Abstract Introduction: Artificial intelligence is transforming healthcare by driving innovation, automation, and optimization across various fields of medicine. The aim of this study was to determine whether artificial intelligence (AI) techniques can be used in the diagnosis, treatment planning, and monitoring of urological cancers. Methodology: We conducted a thorough search for original and review articles published until 31 May 2022 in the PUBMED/Scopus database. Our search included several terms related to AI and urooncology. Articles were selected with the consensus of all authors. Results: Several types of AI can be used in the medical field. The most common forms of AI are machine learning (ML), deep learning (DL), neural networks (NNs), natural language processing (NLP) systems, and computer vision. AI can improve various domains related to the management of urologic cancers, such as imaging, grading, and nodal staging. AI can also help identify appropriate diagnoses, treatment options, and even biomarkers. In the majority of these instances, AI is as accurate as or sometimes even superior to medical doctors. Conclusions: AI techniques have the potential to revolutionize the diagnosis, treatment, and monitoring of urologic cancers. The use of AI in urooncology care is expected to increase in the future, leading to improved patient outcomes and better overall management of these tumors.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] DIURETICS - WHAT WE HAVE AND WHAT WE NEED
    KAU, ST
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1987, 37 (01): : 169 - 170
  • [42] Enterprise Modeling - What We Have Learned, and What We Have Not
    Jorgensen, Havard D.
    PRACTICE OF ENTERPRISE MODELING, PROCEEDINGS, 2009, 39 : 3 - 7
  • [43] What to Expect From Artificial Intelligence
    Agrawal, Ajay
    Gans, Joshua S.
    Goldfarb, Avi
    MIT SLOAN MANAGEMENT REVIEW, 2017, 58 (03) : 23 - 26
  • [44] What should we expect when we explant?
    Landes, Uri
    Harari, Emanuel
    EUROINTERVENTION, 2024, 20 (02) : e115 - e116
  • [45] The Emotional Intelligence, Health, and Well-Being Nexus: What Have We Learned and What Have We Missed?
    Zeidner, Moshe
    Matthews, Gerald
    Roberts, Richard D.
    APPLIED PSYCHOLOGY-HEALTH AND WELL BEING, 2012, 4 (01) : 1 - 30
  • [46] Global change - what do we expect and what do we know?
    Mauser, W
    RESEARCH BASINS AND HYDROLOGICAL PLANNING, 2004, : 53 - 59
  • [47] Nanofluidics: what is it and what can we expect from it?
    Eijkel, JCT
    van den Berg, A
    MICROFLUIDICS AND NANOFLUIDICS, 2005, 1 (03) : 249 - 267
  • [48] Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
    Jennifer Catherine Louise Camaradou
    Henry David Jeffry Hogg
    Advances in Therapy, 2023, 40 : 2563 - 2572
  • [49] Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
    Camaradou, Jennifer Catherine Louise
    Hogg, Henry David Jeffry
    ADVANCES IN THERAPY, 2023, 40 (06) : 2563 - 2572
  • [50] Nanofluidics: what is it and what can we expect from it?
    Jan C. T. Eijkel
    Albert van den Berg
    Microfluidics and Nanofluidics, 2005, 1 : 249 - 267